Experimental monoclonal antibody combo shows significant efficacy against COVID-19
As part of the NIH-sponsored ACTIV-2 clinical trial for COVID-19 outpatients, preliminary data revealed that a new combination monoclonal antibody treatment reduced hospitalizations and death by 78 percent in high-risk patients. ...
Sep 1, 2021
0
19